| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 201 | 2023 | 5358 | 14.680 |
Why?
|
| Antibodies, Monoclonal | 98 | 2022 | 9245 | 5.620 |
Why?
|
| Skin Neoplasms | 80 | 2023 | 5479 | 5.380 |
Why?
|
| Immunotherapy | 68 | 2023 | 4257 | 4.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 58 | 2022 | 11324 | 3.380 |
Why?
|
| Cancer Vaccines | 25 | 2023 | 1009 | 2.740 |
Why?
|
| Antineoplastic Agents | 63 | 2019 | 13576 | 2.670 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 17 | 2023 | 903 | 2.610 |
Why?
|
| Neoplasms | 65 | 2023 | 20941 | 2.070 |
Why?
|
| Uveal Neoplasms | 7 | 2020 | 305 | 1.980 |
Why?
|
| Mucous Membrane | 9 | 2021 | 668 | 1.750 |
Why?
|
| Proto-Oncogene Proteins c-kit | 9 | 2017 | 785 | 1.710 |
Why?
|
| Proto-Oncogene Proteins B-raf | 24 | 2021 | 2004 | 1.710 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 18 | 2020 | 1029 | 1.520 |
Why?
|
| CD8-Positive T-Lymphocytes | 19 | 2021 | 4308 | 1.380 |
Why?
|
| Tumor Microenvironment | 20 | 2023 | 3335 | 1.300 |
Why?
|
| Indoles | 11 | 2019 | 1821 | 1.270 |
Why?
|
| Immunomodulation | 5 | 2019 | 523 | 1.230 |
Why?
|
| Vascular Endothelial Growth Factor A | 8 | 2023 | 3479 | 1.130 |
Why?
|
| Oncolytic Viruses | 3 | 2021 | 318 | 1.080 |
Why?
|
| Antigens, CD | 13 | 2022 | 4052 | 1.080 |
Why?
|
| Pneumonia | 8 | 2021 | 2059 | 1.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 19 | 2022 | 5087 | 1.050 |
Why?
|
| Pyrimidines | 6 | 2017 | 2893 | 1.030 |
Why?
|
| Mutation | 37 | 2022 | 29672 | 1.010 |
Why?
|
| Humans | 331 | 2023 | 725187 | 0.980 |
Why?
|
| Neoplasm Metastasis | 30 | 2022 | 4896 | 0.980 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2018 | 437 | 0.910 |
Why?
|
| T-Lymphocytes, Cytotoxic | 7 | 2019 | 1825 | 0.890 |
Why?
|
| Carcinoma, Renal Cell | 14 | 2020 | 3023 | 0.860 |
Why?
|
| Lung Neoplasms | 25 | 2022 | 12870 | 0.850 |
Why?
|
| Neoplasm Staging | 44 | 2022 | 10950 | 0.840 |
Why?
|
| Aged | 132 | 2022 | 161486 | 0.830 |
Why?
|
| Middle Aged | 147 | 2023 | 212292 | 0.810 |
Why?
|
| Brain Neoplasms | 18 | 2021 | 8657 | 0.780 |
Why?
|
| Disease-Free Survival | 28 | 2019 | 6893 | 0.780 |
Why?
|
| Triazoles | 2 | 2018 | 909 | 0.750 |
Why?
|
| Aged, 80 and over | 67 | 2022 | 57656 | 0.740 |
Why?
|
| Antibodies, Neoplasm | 4 | 2016 | 292 | 0.730 |
Why?
|
| Kaplan-Meier Estimate | 26 | 2019 | 6537 | 0.730 |
Why?
|
| Protein Kinase C | 3 | 2020 | 1239 | 0.720 |
Why?
|
| Treatment Outcome | 70 | 2021 | 61761 | 0.720 |
Why?
|
| Oncolytic Virotherapy | 4 | 2022 | 490 | 0.720 |
Why?
|
| Pyrroles | 3 | 2020 | 1142 | 0.720 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2019 | 63 | 0.710 |
Why?
|
| Antigens, Differentiation | 4 | 2008 | 929 | 0.700 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2021 | 5171 | 0.690 |
Why?
|
| Protein Kinase Inhibitors | 14 | 2019 | 5457 | 0.670 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2020 | 4333 | 0.660 |
Why?
|
| Male | 157 | 2023 | 347096 | 0.660 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 2 | 2014 | 182 | 0.660 |
Why?
|
| Granuloma | 2 | 2018 | 320 | 0.650 |
Why?
|
| Female | 165 | 2023 | 375449 | 0.650 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2018 | 43 | 0.650 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2021 | 8452 | 0.640 |
Why?
|
| Antibodies, Blocking | 4 | 2019 | 250 | 0.630 |
Why?
|
| Lymphoma | 5 | 2022 | 1858 | 0.620 |
Why?
|
| Clinical Trials as Topic | 22 | 2023 | 7840 | 0.620 |
Why?
|
| Antigens, Neoplasm | 14 | 2021 | 1944 | 0.610 |
Why?
|
| Piperazines | 4 | 2014 | 2481 | 0.600 |
Why?
|
| Angiopoietin-2 | 2 | 2016 | 165 | 0.580 |
Why?
|
| Colitis | 7 | 2022 | 1151 | 0.570 |
Why?
|
| Galectin 1 | 1 | 2017 | 133 | 0.560 |
Why?
|
| Adult | 106 | 2023 | 211615 | 0.560 |
Why?
|
| Molecular Targeted Therapy | 14 | 2021 | 2760 | 0.560 |
Why?
|
| Herpesvirus 1, Human | 3 | 2022 | 749 | 0.550 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2021 | 775 | 0.550 |
Why?
|
| Drug Administration Schedule | 17 | 2021 | 4938 | 0.530 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2019 | 871 | 0.530 |
Why?
|
| Sulfonamides | 7 | 2014 | 1882 | 0.530 |
Why?
|
| GTP-Binding Protein alpha Subunits | 2 | 2012 | 96 | 0.520 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2021 | 649 | 0.510 |
Why?
|
| Benzamides | 4 | 2014 | 1372 | 0.510 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2018 | 266 | 0.500 |
Why?
|
| Killer Cells, Natural | 4 | 2023 | 2099 | 0.500 |
Why?
|
| Combined Modality Therapy | 13 | 2022 | 8617 | 0.500 |
Why?
|
| Neovascularization, Pathologic | 5 | 2019 | 2650 | 0.490 |
Why?
|
| Kidney Neoplasms | 10 | 2020 | 4122 | 0.480 |
Why?
|
| Hydroxamic Acids | 1 | 2016 | 496 | 0.470 |
Why?
|
| Survival Rate | 22 | 2021 | 12817 | 0.470 |
Why?
|
| HLA Antigens | 2 | 2018 | 1377 | 0.460 |
Why?
|
| MAP Kinase Kinase Kinases | 5 | 2019 | 263 | 0.460 |
Why?
|
| Clinical Trials, Phase II as Topic | 8 | 2019 | 616 | 0.460 |
Why?
|
| Drug Synergism | 3 | 2016 | 1800 | 0.460 |
Why?
|
| Disease Progression | 23 | 2022 | 13157 | 0.460 |
Why?
|
| T-Lymphocytes | 15 | 2023 | 10007 | 0.450 |
Why?
|
| Inhibitor of Apoptosis Proteins | 4 | 2016 | 218 | 0.450 |
Why?
|
| Radiotherapy | 2 | 2019 | 1543 | 0.440 |
Why?
|
| Prognosis | 29 | 2021 | 28737 | 0.430 |
Why?
|
| Immunity, Humoral | 5 | 2019 | 574 | 0.430 |
Why?
|
| T-Lymphocytes, Regulatory | 9 | 2020 | 2939 | 0.430 |
Why?
|
| Cell Line, Tumor | 23 | 2020 | 16630 | 0.420 |
Why?
|
| Ovarian Neoplasms | 5 | 2020 | 4754 | 0.420 |
Why?
|
| Immunity, Cellular | 3 | 2016 | 1610 | 0.410 |
Why?
|
| Leukocytes, Mononuclear | 9 | 2023 | 1805 | 0.410 |
Why?
|
| Sunlight | 1 | 2013 | 329 | 0.410 |
Why?
|
| Neoplasm Proteins | 8 | 2021 | 3711 | 0.400 |
Why?
|
| Hepatitis | 3 | 2023 | 224 | 0.400 |
Why?
|
| Dose-Response Relationship, Drug | 19 | 2021 | 10971 | 0.400 |
Why?
|
| Immunophenotyping | 7 | 2022 | 1866 | 0.390 |
Why?
|
| Thyroid Diseases | 3 | 2019 | 375 | 0.390 |
Why?
|
| Cell Proliferation | 9 | 2021 | 10477 | 0.380 |
Why?
|
| Quinazolines | 2 | 2020 | 1365 | 0.380 |
Why?
|
| Cytokines | 11 | 2022 | 7180 | 0.360 |
Why?
|
| Melanoma, Experimental | 4 | 2019 | 570 | 0.350 |
Why?
|
| Peptide Fragments | 3 | 2019 | 5037 | 0.350 |
Why?
|
| Medical Oncology | 4 | 2023 | 2162 | 0.340 |
Why?
|
| Apoptosis | 8 | 2021 | 9756 | 0.340 |
Why?
|
| Tumor Burden | 8 | 2022 | 1891 | 0.340 |
Why?
|
| T-Lymphocyte Subsets | 6 | 2019 | 1845 | 0.340 |
Why?
|
| Gene Amplification | 1 | 2013 | 1072 | 0.330 |
Why?
|
| Antibody Formation | 5 | 2016 | 1388 | 0.330 |
Why?
|
| Tumor Escape | 3 | 2021 | 346 | 0.330 |
Why?
|
| Maximum Tolerated Dose | 10 | 2022 | 892 | 0.320 |
Why?
|
| Imidazoles | 6 | 2019 | 1226 | 0.320 |
Why?
|
| Survival Analysis | 15 | 2020 | 10251 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2012 | 588 | 0.320 |
Why?
|
| MAP Kinase Signaling System | 2 | 2012 | 1534 | 0.310 |
Why?
|
| Double-Blind Method | 11 | 2022 | 11883 | 0.310 |
Why?
|
| Diagnostic Imaging | 2 | 2018 | 3460 | 0.300 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2023 | 5215 | 0.300 |
Why?
|
| Autoimmunity | 3 | 2018 | 1320 | 0.290 |
Why?
|
| Tomography, X-Ray Computed | 14 | 2019 | 19908 | 0.290 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2021 | 1829 | 0.290 |
Why?
|
| Hematologic Neoplasms | 2 | 2016 | 1725 | 0.290 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 4 | 2013 | 631 | 0.280 |
Why?
|
| Clinical Trials, Phase III as Topic | 7 | 2018 | 795 | 0.280 |
Why?
|
| Amino Acid Sequence | 4 | 2021 | 13932 | 0.280 |
Why?
|
| Follow-Up Studies | 21 | 2021 | 38748 | 0.280 |
Why?
|
| Tumor Cells, Cultured | 9 | 2021 | 6371 | 0.270 |
Why?
|
| Oximes | 4 | 2019 | 313 | 0.270 |
Why?
|
| Adjuvants, Immunologic | 3 | 2022 | 984 | 0.270 |
Why?
|
| Endocrine System Diseases | 2 | 2018 | 248 | 0.270 |
Why?
|
| Immunization, Passive | 1 | 2008 | 625 | 0.270 |
Why?
|
| Cell Adhesion Molecules | 2 | 2023 | 1615 | 0.260 |
Why?
|
| Rectal Neoplasms | 2 | 2016 | 1141 | 0.250 |
Why?
|
| North America | 2 | 2021 | 1208 | 0.250 |
Why?
|
| Gene Expression Profiling | 13 | 2021 | 9379 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2022 | 8918 | 0.250 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 2912 | 0.250 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 2021 | 0.240 |
Why?
|
| Autoantigens | 1 | 2008 | 885 | 0.240 |
Why?
|
| Young Adult | 25 | 2021 | 55781 | 0.240 |
Why?
|
| Immunologic Factors | 3 | 2021 | 1543 | 0.240 |
Why?
|
| Animals | 46 | 2022 | 168714 | 0.240 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2023 | 1365 | 0.240 |
Why?
|
| Hypothyroidism | 3 | 2019 | 648 | 0.230 |
Why?
|
| NF-kappa B | 1 | 2012 | 2549 | 0.230 |
Why?
|
| Immunohistochemistry | 12 | 2019 | 11484 | 0.230 |
Why?
|
| Immunosuppressive Agents | 4 | 2021 | 4105 | 0.230 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2021 | 370 | 0.220 |
Why?
|
| Tobacco, Smokeless | 1 | 2023 | 129 | 0.220 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2023 | 3400 | 0.220 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2022 | 777 | 0.220 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2011 | 2947 | 0.220 |
Why?
|
| Lymphocytes | 4 | 2020 | 2642 | 0.220 |
Why?
|
| Urologic Neoplasms | 2 | 2018 | 310 | 0.220 |
Why?
|
| Retrospective Studies | 34 | 2023 | 74206 | 0.220 |
Why?
|
| Flow Cytometry | 7 | 2023 | 5968 | 0.210 |
Why?
|
| Immune Tolerance | 3 | 2011 | 2253 | 0.210 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2018 | 317 | 0.210 |
Why?
|